Sanguine BioSciences
Total Raised
$12MInvestors Count
8Deal Terms
1Funding, Valuation & Revenue
8 Fundings
Sanguine BioSciences has raised $12M over 8 rounds.
Sanguine BioSciences's latest funding round was a Loan - II for $6M on October 31, 2023.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
10/31/2023 | Loan - II | $6M | 1 | |||
1/9/2023 | Unattributed - II | |||||
4/8/2020 | Loan | |||||
2/1/2019 | Grant | |||||
6/1/2018 | Seed |
Date | 10/31/2023 | 1/9/2023 | 4/8/2020 | 2/1/2019 | 6/1/2018 |
|---|---|---|---|---|---|
Round | Loan - II | Unattributed - II | Loan | Grant | Seed |
Amount | $6M | ||||
Investors | |||||
Valuation | |||||
Revenue | |||||
Sources | 1 |
Sanguine BioSciences Deal Terms
1 Deal Term
Sanguine BioSciences's deal structure is available for 1 funding round, including their Unattributed from November 25, 2014.
Round | Unattributed |
|---|---|
Funding Date | |
Pre-Money Valuation | |
Post-Money Valuation | |
Amount Raised | |
Shares Authorized | |
Issuance Price | |
Dividend Rate | |
Liquidation Preferences | |
Liquidation Price | |
Participation | |
Conversion Price | |
Anti Dilution | |
General Voting | |
Board Voting | |
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Unattributed |
Sanguine BioSciences Investors
8 Investors
Sanguine BioSciences has 8 investors. Catalio Capital Management invested in Sanguine BioSciences's Loan - II funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
10/31/2023 | 10/31/2023 | 1 Loan - II | Private Equity | Maryland | ||
Investment Bank | California | |||||
Government | DC | |||||
Government | Virginia | |||||
Incubator/Accelerator | New York |
First funding | 10/31/2023 | ||||
|---|---|---|---|---|---|
Last Funding | 10/31/2023 | ||||
Investor | |||||
Rounds | 1 Loan - II | ||||
Board Seats | |||||
Type | Private Equity | Investment Bank | Government | Government | Incubator/Accelerator |
Location | Maryland | California | DC | Virginia | New York |
Compare Sanguine BioSciences to Competitors
First Choice Bio provides primary human and non-human cell samples for research purposes within the biotechnology, life science, pharmaceutical, academic, and governmental sectors. The company offers products including normal and diseased human donor blood, plasma, serum, leukopaks, and various cell types, as well as laboratory services like flow cytometry and next generation sequencing. First Choice Bio delivers fresh samples worldwide within 24 hours and provides laboratory services for sample characterization. It was founded in 2023 and is based in Benicia, California.
MT Group is a biospecimen contract research organization (CRO) that provides biospecimens and related services for pharmaceutical, biotechnology, and diagnostic companies. The company offers biospecimen collections with clinical annotation to support research and development in various medical fields. MT Group serves the pharmaceutical, biotechnology, and diagnostic sectors with its biospecimen-related products and services. It was founded in 2003 and is based in Los Angeles, California.
The Sample Network is involved in the acquisition and delivery of human biological samples for the research and development sectors, operating within the biotechnology and pharmaceutical industries. The company provides services such as biosample collection, support for biomarker development, and assistance in diagnostic and pharmaceutical research. It serves clinical and pharmaceutical research organizations that require biosamples. It was founded in 2021 and is based in Harlow, England.
BioIVT provides biological specimens and services in the precision medicine research sector. The company specializes in control and disease state samples, including human and animal tissues, cell products, blood, and other biofluids, to support precision medicine research. BioIVT also offers hepatic modeling solutions and absorption, distribution, metabolism, excretion, and toxicity (ADME-Tox) model systems to aid in understanding pharmacokinetics and drug metabolism. BioIVT was formerly known as BioreclamationIVT. It was founded in 1981 and is based in Hicksville, New York.
Loading...